Aperio Technologies, Inc. Introduces Industry’s First Digital IHC Solution With Integrated Image Analysis for Quantification of Breast Cancer

VISTA, Calif.--(BUSINESS WIRE)--Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, is pleased to announce the launch of a digital pathology solution for Immunohistochemistry (IHC) designed specifically for the clinical market. Aperio’s digital IHC solution is the only commercially available FDA-cleared system allowing pathologists to run quantitative IHC image analysis while reading slides on a computer monitor.

MORE ON THIS TOPIC